FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134293541> ?p ?o ?g. }

• W3134293541 endingPage "1060" @default.
• W3134293541 startingPage "1060" @default.
• W3134293541 abstract "Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an innovative laparoscopic intraperitoneal chemotherapy approach with the advantage of a deeper tissue penetration. Thus far, oxaliplatin has been administered at an arbitrary dose of 92 mg/m2, cisplatin at 7.5 mg/m2 and doxorubicin 1.5 mg/m2. This is a model-based approach phase I dose escalation study with the aim of identifying the maximum tolerable dose of the three different drugs. The starting dose of oxaliplatin was 100 mg/m2; cisplatin was used in association with doxorubicin: 15 mg/m2 and 3 mg/m2 were the respective starting doses. Safety was assessed according to Common Terminology Criteria for Adverse Events (CTCAE version 4.03). Thirteen patients were submitted to one PIPAC procedure. Seven patients were treated with cisplatin and doxorubicin and 6 patients with oxaliplatin; no dose limiting toxicities and major side effects were found. Common adverse events included postoperative abdominal pain and nausea. The maximum tolerable dose was not reached. The highest dose treated cohort (oxaliplatin 135 mg/m2; cisplatin 30 mg/m2 and doxorubicin 6 mg/m2) tolerated PIPAC well. Serological analyses revealed no trace of doxorubicin at any dose level. Serum levels of cis- and oxaliplatin reached a peak at 60–120 min after PIPAC and were still measurable in the circulation 24 h after the procedure. Cisplatin and doxorubicin may be safely used as PIPAC at a dose of 30 mg/m2 and 6 mg/m2, respectively; oxaliplatin can be used at an intraperitoneal dose of 135 mg/m2. The dosages achieved to date are the highest ever used in PIPAC." @default.
• W3134293541 created "2021-03-15" @default.
• W3134293541 creator A5002753743 @default.
• W3134293541 creator A5003289983 @default.
• W3134293541 creator A5004250774 @default.
• W3134293541 creator A5006968793 @default.
• W3134293541 creator A5017714141 @default.
• W3134293541 creator A5022822406 @default.
• W3134293541 creator A5060727765 @default.
• W3134293541 creator A5065431761 @default.
• W3134293541 creator A5077463120 @default.
• W3134293541 creator A5080884178 @default.
• W3134293541 creator A5086973820 @default.
• W3134293541 date "2021-03-03" @default.
• W3134293541 modified "2023-10-06" @default.
• W3134293541 title "A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis" @default.
• W3134293541 cites W1608726140 @default.
• W3134293541 cites W1853593785 @default.
• W3134293541 cites W1980661013 @default.
• W3134293541 cites W1994039819 @default.
• W3134293541 cites W2011600187 @default.
• W3134293541 cites W2042990006 @default.
• W3134293541 cites W2047640292 @default.
• W3134293541 cites W2049893459 @default.
• W3134293541 cites W2051099595 @default.
• W3134293541 cites W2054485301 @default.
• W3134293541 cites W2080853165 @default.
• W3134293541 cites W2093434729 @default.
• W3134293541 cites W2094916985 @default.
• W3134293541 cites W2099373382 @default.
• W3134293541 cites W2117190139 @default.
• W3134293541 cites W2133768270 @default.
• W3134293541 cites W2162553170 @default.
• W3134293541 cites W2170008162 @default.
• W3134293541 cites W2172807038 @default.
• W3134293541 cites W2344894825 @default.
• W3134293541 cites W2521892896 @default.
• W3134293541 cites W2531203326 @default.
• W3134293541 cites W2561811982 @default.
• W3134293541 cites W2592952952 @default.
• W3134293541 cites W2615552839 @default.
• W3134293541 cites W2621270745 @default.
• W3134293541 cites W2766777872 @default.
• W3134293541 cites W2799675510 @default.
• W3134293541 cites W2944802824 @default.
• W3134293541 cites W2949168788 @default.
• W3134293541 cites W2954661925 @default.
• W3134293541 cites W3022724148 @default.
• W3134293541 cites W3033123563 @default.
• W3134293541 cites W3092200541 @default.
• W3134293541 cites W3097764331 @default.
• W3134293541 doi "https://doi.org/10.3390/cancers13051060" @default.
• W3134293541 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7958944" @default.
• W3134293541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33802269" @default.
• W3134293541 hasPublicationYear "2021" @default.
• W3134293541 type Work @default.
• W3134293541 sameAs 3134293541 @default.
• W3134293541 citedByCount "15" @default.
• W3134293541 countsByYear W31342935412022 @default.
• W3134293541 countsByYear W31342935412023 @default.
• W3134293541 crossrefType "journal-article" @default.
• W3134293541 hasAuthorship W3134293541A5002753743 @default.
• W3134293541 hasAuthorship W3134293541A5003289983 @default.
• W3134293541 hasAuthorship W3134293541A5004250774 @default.
• W3134293541 hasAuthorship W3134293541A5006968793 @default.
• W3134293541 hasAuthorship W3134293541A5017714141 @default.
• W3134293541 hasAuthorship W3134293541A5022822406 @default.
• W3134293541 hasAuthorship W3134293541A5060727765 @default.
• W3134293541 hasAuthorship W3134293541A5065431761 @default.
• W3134293541 hasAuthorship W3134293541A5077463120 @default.
• W3134293541 hasAuthorship W3134293541A5080884178 @default.
• W3134293541 hasAuthorship W3134293541A5086973820 @default.
• W3134293541 hasBestOaLocation W31342935411 @default.
• W3134293541 hasConcept C121608353 @default.
• W3134293541 hasConcept C126322002 @default.
• W3134293541 hasConcept C162156334 @default.
• W3134293541 hasConcept C197934379 @default.
• W3134293541 hasConcept C2776694085 @default.
• W3134293541 hasConcept C2777793932 @default.
• W3134293541 hasConcept C2778239845 @default.
• W3134293541 hasConcept C2780580376 @default.
• W3134293541 hasConcept C2780962732 @default.
• W3134293541 hasConcept C2781303535 @default.
• W3134293541 hasConcept C526805850 @default.
• W3134293541 hasConcept C71924100 @default.
• W3134293541 hasConcept C90924648 @default.
• W3134293541 hasConceptScore W3134293541C121608353 @default.
• W3134293541 hasConceptScore W3134293541C126322002 @default.
• W3134293541 hasConceptScore W3134293541C162156334 @default.
• W3134293541 hasConceptScore W3134293541C197934379 @default.
• W3134293541 hasConceptScore W3134293541C2776694085 @default.
• W3134293541 hasConceptScore W3134293541C2777793932 @default.
• W3134293541 hasConceptScore W3134293541C2778239845 @default.
• W3134293541 hasConceptScore W3134293541C2780580376 @default.
• W3134293541 hasConceptScore W3134293541C2780962732 @default.
• W3134293541 hasConceptScore W3134293541C2781303535 @default.
• W3134293541 hasConceptScore W3134293541C526805850 @default.
• W3134293541 hasConceptScore W3134293541C71924100 @default.

• next